# OnCusp Therapeutics

Source: https://onco.cc/companies/oncusp-therapeutics/  
OnCo record `oncusp-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

OnCusp Therapeutics develops an antibody-drug conjugate aimed at the protein CDH6, mainly for ovarian cancer that no longer responds to platinum chemotherapy.

## Summary

OnCusp Therapeutics, Inc. was founded in April 2021, according to the company, by Bing Yuan, Eric Slosberg and Andy Fu, with offices in New York and Shanghai, to in-license and develop early oncology assets. Its lead programme CUSP06 (AMT-707), licensed ex-China from Multitude Therapeutics, is a CDH6-directed antibody-drug conjugate; it received FDA clearance for a phase 1 trial in August 2023 and dosed its first patient in March 2024 in platinum-refractory or resistant ovarian cancer and other advanced solid tumours (NCT06234423), with phase 1b data in platinum-resistant ovarian cancer presented at IGCS 2026. The company reports a USD 25 million seed (2021), a USD 14 million seed plus (2022) and a USD 100 million Series A (December 2023). Its first registered cancer trial, NCT06234423, was posted on ClinicalTrials.gov in January 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: OnCusp Therapeutics, Inc.
- HQ: New York, NY
- Type: biotech
- Website: https://www.oncusptx.com/

## Notes

- Founding date, offices and rounds from the company milestones on its About page, read on 29 October 2026; the individual financing releases were not read and investors are not recorded. The New York headquarters is inferred from the company's New York office; the site does not name a head office.

## Sources

- Official website: https://www.oncusptx.com/
- About and milestones: https://www.oncusptx.com/aboutus/index.html
- Company news: https://www.oncusptx.com/companynews/index.html
- ClinicalTrials.gov: phase 1 trial of CUSP06 (NCT06234423): https://clinicaltrials.gov/study/NCT06234423

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [CDH6](https://onco.cc/targets/cdh6/)

---
JSON: https://onco.cc/api/v1/entities/oncusp-therapeutics.json